Member Info for Mafuta

https://twitter.com/sparksinsurrey/status/1504140294325174272?t=dDMZlKoDnTk8frJPVzSlpQ&s=19

Sierra finished 7.6% up today ...

To put this into context we closed at around 117p Friday and closed today at 140p that's over 19% rise and that's not too shabby ... and the market has not caught up yet ... such a shame we were hammered on the low volume post consolidation ... otherwise we would have been around 200p ... but hey ho ... there's more news to come and the vultures are circling ... patience will pay off ... must go ...
"Musha ring dum a doo dam a da
Whack for my daddy-o
Whack for my daddy-o
There's whiskey in the jar-o"

Love hugs and kisses Mafuta

https://twitter.com/MEDiSTRAVA_Cons/status/1504106280260190215?t=U0xpDuGGgDUSg72gN5zIQw&s=19

My point is it's really irrelevant how long you have been invested ... That you actually ARE is highly relevant ... but I guess it's all in the game ... Love hugs and kisses Mafuta

Why do some posters have to state they are a LTH ... it's not that it really matters does it?

But though the following was reasonably well balanced:

https://www.asktraders.com/analysis/sareum-sar-shares-surged-11-7-as-its-sdc-1801-drug-heads-for-clinical-trials/

I repeat ... (yawn) ... there are some among us that will be able to read and interpret a tox report ... But to be honest the majority would not ... the BOD will not release the details for commercial reasons ... nothing more sinister than that ... what we will get is a little more detail in the CTA application such as the range of conditions targeted and the duration ... anything else will be seen as on a "need to know" basis and quite frankly most don't need to know at this stage ... Just calm down we are on track and the big boys are watching from the sidelines ... Love hugs and kisses Mafuta

Whilst the market may have not responded the way some would have liked, the pharmaceuticals will have read the RNS with interest. This will have added millions to our IP and they must be getting quite twitchy ... who will be the first to up their offer?

The toxicity profile will be in the report with weighted averages for each tissue type ... but ... 1. This information is commercially sensitive 2. It is unlikely that many here would be able to interpret the pharmacological implications and 3. The information we have received is sufficient to guide our investment strategies. Looking forward to a very blue day ... Love hugs and kisses Mafuta

Just want to say many thanks to Wally for his comprehensive notes. It is much appreciated... Mafuta

The Company has now received the final signed report from the Contract Research Organisation that conducted these studies and, as previously reported, these data fully support the Company's plan to submit a CTA application in mid-2022 and to commence a Phase 1a clinical trial with SDC-1801 in H2 2022

Sad I think you are spot on. Hopefully something will come from the conference today. SteadyDanny highlighted the potential of 737 which I had presumed was well on the back burner ... Guess we have to see what pans out ... Whatever the case there's a lot going for us at the moment. All the best Mafuta

I think some may be a bit unaware of how complex a toxicology report is ... It's not something to give some tottie for typing (is that 70s enough for you?) And just send it out after a quick spell check ... It needs to be precise and contain all the relevant information that will enable a focused CTA to be lodged ... It's probably already 99% there but needs to be spot on ... The best we will get is a confirmation of what has already been said and hopefully a scope statement for the CTA ... Anyhow it's nice to see some blue numbers for a change. Love hugs and kisses Mafuta

Qd22 as far as I can remember ARMS Medical is the distributor for their urogynaecological products, mainly for vaginal prolapse repair.

Financial Highlights

· Returned to double digit revenue growth up 20% to US$19.7m (2020: US$16.5m) due to a strong performance in the US

o BioRinse® (orthopaedics and dental) revenue of US$12.7m, up 33% (2020: US$9.5m)

o Joint venture GBM-v increased revenue of US$2.8m, up 5% (2020: US$2.6m)

o dCELL® (DermaPure®) sales remained consistent at US$4.2m (2020: US$4.2m)

· Gross Profit increased to US$8.5m (2020: US$7.5m)

· Operating Loss reduced to US$4.9m (2020: US$12.4m)

· Cash balance at 31 December 2021 of US$7.7m, supports current business growth plan



Operational Highlights

· Completion of the Phase 1 facility expansion at the San Antonio, Texas facility, in June 2021 on time and on budget

· Launch of dCELL® product line extensions; DermaPure® Meshed, VNEW™ and MatrixND™

· Reorganisation of the dCELL® commercial operations to reinvigorate sales growth

· Successfully secured several new strategic partners and distributors resulting in a 36% increase in units shipped during 2021

· ISO 13485 accreditation for the Garforth, Leeds facility received in February 2021

· Completion of restructuring of the dCELL® operations in January 2021 which will reduce the overhead cost base by c. US$700k on an annualised basis

· Sales for DermaPure® products to ARMS Medical were up 24%

SEC filings
Interesting

Professor Adrian Esterman, a former World Health Organisation (WHO) epidemiologist, told ABC news, that although the new sub-variant is not any more severe than Omicron, it is more transmissible. He said: “That means we’re going to see case numbers skyrocketing.”

On his Twitter account, he added: “Omicron BA.2 is about 1.4 times more infectious than BA.1. The basic reproduction number (R0) for BA.1 is about 8.2, making R0 for BA.2 about 12.

The decision here is quite simple ... you either trust the science, the IP value, and the bod... If you do you accumulate at these levels and hold ... Or you don't trust the science, the IP value, and the bod, you sell and cut your losses ... It's a basic investment decision ... All the complaining and moaning about the SP and how the bod and the MM (as crooked as they may be) are to blame won't help just sell up and go elsewhere ... Not being sympathetic in the stock market just doesn't cut the mustard ... It's your money make your own decision but don't sit here moaning and looking for someone to blame ... Whatever the case have a good weekend ... Love, hugs and kisses Mafuta

And it's not beyond a canny LTH with funds to join the fray to accumulate more ... Just saying ... It's your money folks ... Make your own minds up ... xxx Mafuta